Tao Synergies Inc (TAOX)

$5.37 -0.06 (-1.10%)
Market Cap 43.35M
Revenue (ttm) 0.00
Net Income (ttm) -12.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 72,500
Avg Vol 218,282
Day's Range N/A - N/A
Shares Out 7.45M
Stochastic %K 62%
Beta 1.98
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.

Industry: Software - Infrastructure
Sector: Technology
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
SnoopyPotter
SnoopyPotter Jan. 15 at 5:25 PM
$TAOX wish it would make some moves like GTAO Greyscale. should’ve sold when it was $10
0 · Reply
JohnnyP5
JohnnyP5 Jan. 14 at 11:32 PM
$TAOX good move today. More to come. Love the model. 👍
0 · Reply
EndGame1
EndGame1 Jan. 14 at 2:30 AM
$TAOX TAO coin finally moved up to number 49 again. https://www.coingecko.com/
0 · Reply
EndGame1
EndGame1 Jan. 12 at 8:20 PM
$TAO.X $TAOX My TAO Synergies position and $ASST Strive position are within $2000 of each other as my number 2 and 3 holdings in my portfolio.
1 · Reply
www_larval_com
www_larval_com Jan. 8 at 8:57 PM
$ERAS -7%[12%] $TAOX 4%[11%] $ICON -3%[12%] $FEED 3%[11%] most notable movement into the final minutes of trading.
0 · Reply
SnoopyPotter
SnoopyPotter Jan. 6 at 9:57 PM
$TAOX WHy can’t we be like $GTAO
1 · Reply
SnoopyPotter
SnoopyPotter Jan. 6 at 3:28 PM
$TAOX is quietly positioning itself as the pure-play winner in the Bittensor ($TAO.X) explosion While GTAO (Grayscale Bittensor Trust) trades OTC at ~$13.95 with passive 0.0192 $TAO.X/share + 2.5% fees and no staking...$TAOX (Nasdaq-listed) is actively stacking — holding over 54,000 $TAO.X (largest public holder) + earning staking rewards to compound holdings daily. That's real growth baked in, not just tracking. 2/ Why $TAOX benefits massively right now:$TAO.X pumping hard (~$290+, +10%+ today) → direct NAV boost for TAOX's treasury Stock ripping +10%+ to ~$5 range (pre-market heat to $5.33) on ETF filing buzz + broader DeAI hype Active accumulation + staking = higher effective $TAO.X exposure per share than GTAO's static structure No massive expense drag like 2.5% fees eating returns yearly
1 · Reply
SnoopyPotter
SnoopyPotter Jan. 6 at 1:38 PM
$TAOX Let's keep it moving Year of Da Horse = MOMENTUM invest in subnets like Hippius, Ridges, Chutes, Templar
0 · Reply
TaoistTrader
TaoistTrader Jan. 6 at 12:46 PM
$TAO.X it lags behind it bro. well I am invested in $TAOX which is a Tao treasury. AnD that’s what happened to TAOX
0 · Reply
TaoistTrader
TaoistTrader Jan. 5 at 7:13 PM
$TAOX the knowledge gap needs to be bridged. I did mention Tao to one of my investing buddies and he looked at me like he just saw a ghost. $TAO
1 · Reply
Latest News on TAOX
Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

Nov 18, 2025, 5:15 PM EST - 2 months ago

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

BEX CSEX NNEX SNPX

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Nov 18, 2025, 9:15 AM EST - 2 months ago

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms

Nov 13, 2025, 1:37 PM EST - 2 months ago

Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms

BEX CSEX NNEX SNPX

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

Nov 13, 2025, 6:46 AM EST - 2 months ago

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

BEX CSEX NNEX SNPX

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

Nov 11, 2025, 11:26 AM EST - 2 months ago

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

BEX CSEX NNEX SNPX

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

Nov 4, 2025, 9:15 AM EST - 2 months ago

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

Oct 20, 2025, 9:15 AM EDT - 3 months ago

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

TAO Synergies Announces $11 Million Private Placement

Oct 13, 2025, 5:09 PM EDT - 3 months ago

TAO Synergies Announces $11 Million Private Placement

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

Sep 22, 2025, 9:15 AM EDT - 4 months ago

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Sep 8, 2025, 9:15 AM EDT - 4 months ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

Aug 26, 2025, 9:15 AM EDT - 5 months ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 7 months ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 7 months ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 7 months ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 7 months ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 1 year ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 1 year ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 2 years ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 3 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

5 Health Care Stocks That Are Diving - And May Rally

Jan 19, 2023, 8:58 AM EST - 3 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE IPSC TECH

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Dec 9, 2022, 11:50 AM EST - 3 years ago

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 4 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Nov 16, 2021, 11:07 PM EST - 4 years ago

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

Nov 15, 2021, 9:28 AM EST - 4 years ago

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

BTBT HUDI

SnoopyPotter
SnoopyPotter Jan. 15 at 5:25 PM
$TAOX wish it would make some moves like GTAO Greyscale. should’ve sold when it was $10
0 · Reply
JohnnyP5
JohnnyP5 Jan. 14 at 11:32 PM
$TAOX good move today. More to come. Love the model. 👍
0 · Reply
EndGame1
EndGame1 Jan. 14 at 2:30 AM
$TAOX TAO coin finally moved up to number 49 again. https://www.coingecko.com/
0 · Reply
EndGame1
EndGame1 Jan. 12 at 8:20 PM
$TAO.X $TAOX My TAO Synergies position and $ASST Strive position are within $2000 of each other as my number 2 and 3 holdings in my portfolio.
1 · Reply
www_larval_com
www_larval_com Jan. 8 at 8:57 PM
$ERAS -7%[12%] $TAOX 4%[11%] $ICON -3%[12%] $FEED 3%[11%] most notable movement into the final minutes of trading.
0 · Reply
SnoopyPotter
SnoopyPotter Jan. 6 at 9:57 PM
$TAOX WHy can’t we be like $GTAO
1 · Reply
SnoopyPotter
SnoopyPotter Jan. 6 at 3:28 PM
$TAOX is quietly positioning itself as the pure-play winner in the Bittensor ($TAO.X) explosion While GTAO (Grayscale Bittensor Trust) trades OTC at ~$13.95 with passive 0.0192 $TAO.X/share + 2.5% fees and no staking...$TAOX (Nasdaq-listed) is actively stacking — holding over 54,000 $TAO.X (largest public holder) + earning staking rewards to compound holdings daily. That's real growth baked in, not just tracking. 2/ Why $TAOX benefits massively right now:$TAO.X pumping hard (~$290+, +10%+ today) → direct NAV boost for TAOX's treasury Stock ripping +10%+ to ~$5 range (pre-market heat to $5.33) on ETF filing buzz + broader DeAI hype Active accumulation + staking = higher effective $TAO.X exposure per share than GTAO's static structure No massive expense drag like 2.5% fees eating returns yearly
1 · Reply
SnoopyPotter
SnoopyPotter Jan. 6 at 1:38 PM
$TAOX Let's keep it moving Year of Da Horse = MOMENTUM invest in subnets like Hippius, Ridges, Chutes, Templar
0 · Reply
TaoistTrader
TaoistTrader Jan. 6 at 12:46 PM
$TAO.X it lags behind it bro. well I am invested in $TAOX which is a Tao treasury. AnD that’s what happened to TAOX
0 · Reply
TaoistTrader
TaoistTrader Jan. 5 at 7:13 PM
$TAOX the knowledge gap needs to be bridged. I did mention Tao to one of my investing buddies and he looked at me like he just saw a ghost. $TAO
1 · Reply
TaoistTrader
TaoistTrader Jan. 5 at 6:16 PM
$SN13.X $SN3.X $SN4.X $TAO.X interesting thanks for sharing the subnet trackers, I didn’t know that was a thing on ST. I think the Tao ecosystem is confusing. It confuses me to be honest. But breaking down these subnets will help understanding. And I think that’s important going forward. As @jaltucher expained on his podcast. As more people begin to familiarize with the Tao concept.., that’s when the fun begins $TAOX
0 · Reply
Orangotango
Orangotango Jan. 5 at 1:36 PM
$TAO.X $TAOX Monkey likes
0 · Reply
TaoistTrader
TaoistTrader Jan. 4 at 11:47 AM
$TAO.X $TAOX
1 · Reply
EndGame1
EndGame1 Jan. 2 at 6:01 PM
$TAOX A few months ago I sold 500 of my shares for $10/share. Bought them back $7. This time looking for $15/share.
0 · Reply
EndGame1
EndGame1 Jan. 2 at 5:26 PM
$ASST OT if you don’t own any $TAOX you may want to research this one too.
0 · Reply
EndGame1
EndGame1 Jan. 2 at 4:35 PM
$TAOX So glad I called my broker at schwab to buy more Wednesday. Did the same with $DGXX They are making it hard, but that will change or clients will leave them.
1 · Reply
EndGame1
EndGame1 Jan. 2 at 3:38 AM
$TAOX TAO coin 10 day high pre stock market open.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 31 at 10:31 PM
$TAOX Current Stock Price: $3.63
0 · Reply
bobtheunbuilder
bobtheunbuilder Dec. 31 at 8:12 PM
$TAOX market cap up 9x and share price flat. Enough said.
0 · Reply
EndGame1
EndGame1 Dec. 31 at 7:59 PM
$TAOX Can't believe I got another 1000K shares at $3.57. This will triple in 2026. I love last day of the year trading. Schwab wouldn't even let me buy online. They suck for small cap stock trading lately.
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 31 at 5:22 AM
$TAOX Current Stock Price: $3.79
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 2:48 AM
$TAOX
0 · Reply